Breaking News

Financial Report: PAREXEL

April 30, 2014

Revenues up 18% in the quarter

3Q Revenues: $577.9 million (+10%)
3Q Earnings: $34.7 million (+18%)
YTD Revenues: $1.7 billion (+14%)
YTD Earnings: $89.0 million (+35%)
Comments: Clinical Research Services (CRS) revenue was $373.2 million in the quarter, up 9%. PAREXEL Consulting (PC) revenue was $51.9 million, up 3%. PAREXEL Informatics (PI) revenue was $67.3 million, up 9%. Backlog at the end of March 2014 was $4.9 billion, an increase of 9%, including new business wins of $781.6 million in the quarter, and cancellations of $208.7 million.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision